BNBX logo

BNB PLUS CORP

BNBXNASDAQ
🏆 #5299 by market capUS Equity
$0.16—
Last available close · quote unavailable
🔔
Track BNBX
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d▲ 0.0%
14d▲ 0.0%
30d▲ 0.0%
ytd▼ 87.2%
1y▼ 95.7%
🏦Market Cap
$570,144
Small Cap
📈Revenue Growth (YoY)
-44.8%
Declining
📊Gross Margin
46.8%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
0.3x
Cheap
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
—
52-Week Range
$0.07 – $4.35
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
6.2M
Next Earnings
—

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
0.3x
EPS (TTM)
$-15.47
Dividend Yield
—
Dilution (1yr)
+21180.0%
BNBX logo

BNB PLUS CORP

BNBX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2M▼ −37.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
39.3%▲ +32.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$16M▲ +14.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
8.9M▲ +21180.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$6M YoY
StockOtter · stockotter.space

About BNB PLUS CORP

BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.